Akèy › Kansè poumon › Michigan
Etid klinik pou Kansè poumon nan Michigan
44 etid pou Kansè poumon ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
- Ann Arbor23 etid
- Detroit20 etid
- Grand Rapids14 etid
- Lansing11 etid
- Livonia10 etid
- Flint10 etid
- Canton9 etid
- Waterford9 etid
- Farmington Hills8 etid
- Troy6 etid
- Saginaw6 etid
- Clinton Township6 etid
- Kalamazoo6 etid
- Warren6 etid
- Dearborn6 etid
- Wyoming5 etid
- Jackson3 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 50 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 68 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- ak 20 plis
Ap rekriteFaz 3
Laj 70 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ak 27 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 38 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Corewell Health - Butterworth Hospital, Grand Rapids
- Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
- Corewell Health - Research Specimen Processing Area, Grand Rapids
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401A Registry for People With Lung Cancer
- University of Michigan (Data Collection Only), Ann Arbor
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06424327A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0418, Ann Arbor
- Local Institution - 0405, Detroit
- Local Institution - 0420, Traverse City
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07063745Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Profound Research, LLC, Farmington Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Michigan, Ann Arbor
- The Cancer & Hematology Centers, Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Henry Ford Cancer - Detroit, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- ak 13 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Henry Ford Cancer Institute, Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07185997Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- University of Michigan, Ann Arbor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07499674Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Wayne State University/Karmanos Cancer Institute, Detroit
- Weisberg Cancer Treatment Center, Farmington Hills
- McLaren Cancer Institute-Flint, Flint
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- McLaren Cancer Institute-Bay City, Bay City
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 41 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05624996A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- START - Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Henry Ford Cancer- Detroit, Detroit
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT07339059Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06162221Gilteritinib for the Treatment of ALK NSCLC
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06225427Prediction Augmented Screening Initiative
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Ap rekrite
Laj 50 a 80 · Tout sèks · Mizajou Jun 26, 2026 · NCT06538636Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jun 26, 2026 · NCT04614103Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ak 19 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572A Study of ZW251 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT07164313Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ak 14 plis
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ak 7 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06616584A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- University of Michigan, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT07020221A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 18, 2026 · NCT06244771Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 19, 2026 · NCT02984761EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 27, 2026 · NCT05467748A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT07291414Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.